ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China

Li, Jian; Zhang, Jun; Zhang, Yanqiao; Qiu, Haibo; Zhou, Yanbing; Zhou, Yongjian; Zhang, Xinhua; Zhou, Ye; Zhu, Yuping; Li, Yong; Wang, Ming; Shen, Kuntang; Tao, Kaixiong; Wu, Xin; Wang, Haijiang; Zhang, Bo; Ling, Jiayu; Ye, Yingjiang; Wu, Xingye; Qu, Hongyan; Ma, Yue; Jiao, Xuelong; Zheng, Hualong; Jin, Jiejie; Liu, Zhuo; Tan, Ming; Fang, Yong; Zhang, Peng; Zhang, Nan; Lei, Cheng; Cai, Zhaolun; Liang, Bin; Peng, Zhangyan; Huang, Zhao; Dong, Juan; Shen, Lin*复旦大学; 北京大学; 华中科技大学; 青岛大学; 上海交通大学; 哈尔滨医科大学; 河北医科大学; 四川大学; 中山大学; 中国科学院研究生院; 6; 1
European Journal of Cancer2024-1DOI: 10.1016/j.ejca.2023.113439
19阅读
引用收藏
分享

摘要

Aim: A bridging study of INTRIGUE study to assess the efficacy and safety of ripretinib versus sunitinib as second -line treatment in Chinese GIST patients. Methods: This was a phase 2, multicenter, randomized, open-label study in China. GIST patients previously treated with imatinib were randomized (1:1) to receive ripretinib 150 mg once daily (QD) by continuous dosing in 42-day cycles or sunitinib 50 mg QD in 42-day cycles (four weeks on/two weeks off). Primary endpoint was progression-free survival (PFS) by independent radiological review (IRR). Results: Between 6 December 2020 and 15 September 2021, 108 patients were randomized to receive ripretinib (n = 54) or sunitinib (n = 54) (all-patient [AP] intention-to-treat [ITT] population). Seventy patients had pri-mary KIT exon 11 mutations (ripretinib, n = 35; sunitinib, n = 35; Ex11 ITT population). By data cut-off (20 July 2022), in AP ITT population, PFS by IRR was comparable between ripretinib and sunitinib arms (HR 0.99, 95 % CI 0.57, 1.69; nominal p = 0.92; median PFS [mPFS] 10.3 vs 8.3 months). In Ex11 ITT population, PFS by IRR was longer for ripretinib than sunitinib (HR 0.46, 95 % CI 0.23, 0.92; nominal p = 0.03; mPFS not reached in ripretinib arm and 4 & sdot;9 months in sunitinib arm). Fewer patients experienced grade 3/4 treatment-related treatment-emergent adverse events with ripretinib (17%) versus sunitinib (56%). Conclusions: Ripretinib demonstrated similar efficacy and a favorable safety profile versus sunitinib as second -line treatment in Chinese GIST patients. Furthermore, ripretinib provided greater clinically meaningful benefit versus sunitinib in patients with KIT exon 11 mutation.

学科与关键词

关键词
RipretinibSunitinibSecond -line treatmentGastrointestinal stromal tumor
相关
加载中…
  • Efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2 multicenter, randomized, openlabel study in China.
    Li, Jian; Zhang, Jun; Zhang, Yanqiao; Qiu, Haibo; Zhou, Yanbing; Zhou, Yongjian; Zhang, Xinhua; Zhou, Ye; Zhu, Yuping; Li, Yong; Wang, Ming; Shen, Kuntang; Tao, Kaixiong; Wu, Xin; Wang, Haijiang; Zhang, Bo; Ling, Jiayu; Ye, Yingjiang; Dong, Juan; Shen, LinGenitourinary Cancers Symposium, San Francisco, CA, 2023-01-19 To 2023-01-21.被引 1
  • Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study
    Li, Jian; Zhang, Xinhua; Deng, Yanhong; Wu, Xin; Zheng, Zhichao; Zhou, Yongjian; Cai, Shirong; Zhang, Yanqiao; Zhang, Jun; Tao, Kaixiong; Cui, Yuehong; Cao, Hui; Shen, Kuntang; Yu, Jiren; Zhou, Ye; Ren, Wenxiao; Qu, Chenglin; Zhao, Wanqi; Hu, Jin; Wang, Wei; Yang, Jason; Shen, Lin*ONCOLOGIST, 2023, 28(2): 187-+.被引 3
  • Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study
    Zhou, Yongjian; Zeng, Chunling; Sun, Xiaofeng; Zhang, Jun; Qu, Hongyan; Zhang, Xinhua; Zhou, Ye; Liu, Zimin; Wu, Xiaojun; Wu, Xin; Jiao, Xuelong; Shen, Lin; Zhou, Yanbing*; Wang, Yuexiang*; Li, Jian*ONCOLOGIST, 2023.
查看全部 →

发表信息

论文状态
公开发表
期刊
European Journal of Cancer
发表日期
2024-01
卷期
第 196 卷
页码
113439
DOI
10.1016/j.ejca.2023.113439
语言
ENGLISH
成果收录
SCIE
资助标注
Zai Lab (Shanghai) Co., Ltd.

作者

  • L

    Li, Jian (第一作者)

    peking univ canc hosp & inst

  • Z

    Zhang, Jun

    1 · chongqing med univ

查看全部 36 位作者收起作者
  • Z

    Zhang, Yanqiao

    harbin med univ

  • Q

    Qiu, Haibo

    sun yat sen univ

  • Z

    Zhou, Yanbing

    qingdao univ

  • Z

    Zhou, Yongjian

    fujian med univ

  • Z

    Zhang, Xinhua

    1 · sun yat sen univ

  • Z

    Zhou, Ye

    fudan univ

  • Z

    Zhu, Yuping

    univ chinese acad sci · zhejiang canc hosp

  • L

    Li, Yong

    hebei med univ

  • W

    Wang, Ming

    shanghai jiao tong univ

  • S

    Shen, Kuntang

    fudan univ

  • T

    Tao, Kaixiong

    huazhong univ sci & technol

  • W

    Wu, Xin

  • W

    Wang, Haijiang

    xinjiang med univ

  • Z

    Zhang, Bo

    sichuan univ

  • L

    Ling, Jiayu

    6 · sun yat sen univ

  • Y

    Ye, Yingjiang

    peking univ

  • W

    Wu, Xingye

  • Q

    Qu, Hongyan

    harbin med univ

  • M

    Ma, Yue

    harbin med univ

  • J

    Jiao, Xuelong

    qingdao univ

  • Z

    Zheng, Hualong

    fujian med univ

  • J

    Jin, Jiejie

    fudan univ

  • L

    Liu, Zhuo

    univ chinese acad sci · zhejiang canc hosp

  • T

    Tan, Ming

    hebei med univ

  • F

    Fang, Yong

    univ chinese acad sci · zhejiang canc hosp

  • Z

    Zhang, Peng

  • Z

    Zhang, Nan

    chinese peoples liberat army gen hosp

  • L

    Lei, Cheng

    sichuan univ

  • C

    Cai, Zhaolun

    sichuan univ

  • L

    Liang, Bin

    peking univ

  • P

    Peng, Zhangyan

  • H

    Huang, Zhao

  • D

    Dong, Juan

  • S

    Shen, Lin (通讯)

    peking univ canc hosp & inst

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417